is a receptor for retinoic acid, a potent mammalian morphogen and teratogen that has profound effects on vertebrate development. RARA is a member of the nuclear receptor superfamily. Controls cell function by directly regulating gene expression. Its phosphorylation is crucial for transcriptional activity. Aberrations involving RARA may be a cause of acute promyelocytic leukemia. Two splice-variant isoforms have been described. Note: This description may include information from UniProtKB.
Protein type: DNA-binding; Nuclear receptor; Transcription factor; Oncoprotein
Molecular Function: alpha-actinin binding; chromatin DNA binding; enzyme binding; protein binding; protein domain specific binding; protein heterodimerization activity; protein kinase A binding; protein kinase B binding; receptor binding; retinoic acid binding; retinoic acid receptor activity; transcription coactivator activity; transcription corepressor activity; transcription factor activity; transcription factor binding
Biological Process: apoptotic cell clearance; negative regulation of granulocyte differentiation; negative regulation of interferon-gamma production; negative regulation of transcription, DNA-dependent; negative regulation of tumor necrosis factor production; positive regulation of binding; positive regulation of cell cycle; positive regulation of cell proliferation; positive regulation of interleukin-13 production; positive regulation of interleukin-4 production; positive regulation of interleukin-5 production; positive regulation of T-helper 2 cell differentiation; positive regulation of transcription from RNA polymerase II promoter; positive regulation of transcription, DNA-dependent; protein amino acid phosphorylation; response to retinoic acid; retinoic acid receptor signaling pathway; signal transduction; transcription initiation from RNA polymerase II promoter
LTP: The number of records in which this modification site was determined using site-specific methods. SS methods include amino acid sequencing, site-directed mutagenesis, modification site-specific antibodies, specific MS strategies, etc.